02009nas a2200301 4500000000100000008004100001653002600042653001900068653002400087653001200111653001800123653003400141653001700175653001900192100001200211700001200223700001300235700001600248700001400264700001300278700001200291245014900303856007900452300000600531490000600537520115000543022001401693 2014 d10aVector-borne diseases10aVector control10aVaccine development10aMalaria10aLeishmaniasis10aHuman African Trypanosomiasis10aChemotherapy10aChagas disease1 aZofou D1 aNyasa R1 aNsagha D1 aNtie-Kang F1 aMeriki HD1 aAssob JC1 aKuete V00aControl of malaria and other vector-borne protozoan diseases in the tropics: enduring challenges despite considerable progress and achievements. uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895778/pdf/2049-9957-3-1.pdf a10 v33 a

Vector-borne protozoan diseases represent a serious public health challenge, especially in the tropics where poverty together with vector-favorable climates are the aggravating factors. Each of the various strategies currently employed to face these scourges is seriously inadequate. Despite enormous efforts, vaccines-which represent the ideal weapon against these parasitic diseases-are yet to be sufficiently developed and implemented. Chemotherapy and vector control are therefore the sole effective attempts to minimize the disease burden. Nowadays, both strategies are also highly challenged by the phenomenon of drug and insecticide resistance, which affects virtually all interventions currently used. The recently growing support from international organizations and governments of some endemic countries is warmly welcome, and should be optimally exploited in the various approaches to drug and insecticide research and development to overcome the burden of these prevalent diseases, especially malaria, leishmaniasis, Human African Trypanosomiasis (HAT), and Chagas disease.

 

 

 

 a2049-9957